VGX-410

also known as Mifepristone

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Comparator or background therapy1 trial
Phase 2	NCT00255177 Comparator	Nov 2005 → Sep 2007	hepatitis C virus infection	VGX Pharmaceuticals, LLC	Completed	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	VGX-410	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00255177 ↗
Known as	Mifepristone	“VGX-410 (Mifepristone)” NCT00255177 ↗
Action	Inhibit	“VGX-410 represents the first drug in a novel class of HCV IRES inhibitors under development.” NCT00255177 ↗
Modality	Small molecule	“VGX-410 is an orally active and bioavailable, small-molecule, organic drug.” NCT00255177 ↗